...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis
【24h】

Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis

机译：基于铂族的新辅助化疗，用于三阴性乳腺癌：系统评价和荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Triple-negative breast cancer (TNBC) is associated with higher aggressiveness and mortality than hormone-positive breast cancer because of the lack of approved therapeutic targets. Patients with TNBC who attain a pathological complete response (pCR) after neoadjuvant chemotherapy have improved survival. Platinum-based agents show promising activity in TNBC; however, their use remains controversial. We conducted a meta-analysis to assess the role of platinum-based agents in neoadjuvant chemotherapy in patients with TNBC. Methods We performed an extensive literature search of the Pubmed, Embase, and Cochrane databases. We calculated pooled odds ratios (OR) with 95% confidence intervals (CI) for the identified studies. Results Eight randomized controlled trials with 1345 patients were included in the analysis. The addition of platinum-based agents improved pCR compared with neoadjuvant therapy based on anthracyclines, cyclophosphamide, taxanes, and fluorouracil (49.1% vs. 35.9%; OR: 1.87, 95% CI: 1.23–2.86). Hematological adverse events were similar in both groups, except for more thrombocytopenia in the platinum-based group (OR: 7.96, 95% CI: 3.18–19.93). Conclusion The addition of platinum-based agents to neoadjuvant chemotherapy improved pCR rates in patients with TNBC, with a slight increase in hematological toxicities. Platinum-based agents might thus be an accessible and economically viable option in patients with TNBC.
机译：背景，由于缺乏批准的治疗目标，三重阴性乳腺癌（TNBC）与激素阳性乳腺癌的侵袭性和死亡率相关。患有TNBC的患者在新辅助化疗后获得病理完全反应（PCR），提高了存活。基于铂族的代理商在TNBC中显示出有希望的活动;但是，他们的使用仍然存在争议。我们进行了一个荟萃分析，以评估铂族基因在TNBC患者Neoadjuvant化疗中的作用。方法我们对PubMed，Embase和Cochrane数据库进行了广泛的文献搜索。我们计算汇集的差距（或），具有95％的置信区间（CI），用于确定的研究。结果分析中含有8例随机对照试验，含有1345名患者。与基于蒽环素，环膦酰胺，紫杉烷和氟尿嘧啶的新辅助治疗（49.1％vs.35.9％;或：1.87,95％CI：1.23-2.86）相比，添加了PCR的加入PCR改善了PCR。两组血液不良事件相似，除了基于铂族中的更多血小板减少症（或：7.96,95％CI：318-19.93）。结论将铂类药剂添加到Neoadjuvant Chemotherapy中，TNBC患者的PCR率改善，血液学毒性略有增加。因此，基于铂族的药剂可以是TNBC患者的可访问和经济上可行的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号